Clinical Trial Update: Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients [Phase 4]

View source ↗

Summary

A Phase 4 post-marketing registry study evaluating infliximab injections in Chinese pediatric Crohn's disease patients is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd | Conditions: Crohn Disease | Phase 4 | Status: RECRUITING